Biotech company TheraVab to implement IP management on dClinic’s Blockchain

Industry: BlockChain

US and Singaporean Biotech company, TheraVab, is implementing their IP lifecycle and management on dClinic’s Private Healthcare Blockchain (PHB).

Singapore (PRUnderground) July 2nd, 2020

More Biotech companies are starting to see the very real cost savings they can obtain using blockchain for the management of their IP, Clinical Trials and Supply Chain, to name only a few areas of their operations. Investors and management can now very clearly see where they are spending their investments and budgets respectively, with clarity that was previous extremely labour intensive to report on.

“Continuous improvement and effective innovation are key features of pharmaceutics and biotechnology. In addition to offering innovative healthcare solutions, TheraVab looks to implement its IP management on the blockchain to drive shorter drug development cycles and establish secure collaboration with industry and academic partners. We have spent the last 6 months reviewing a number of blockchain solutions, and dClinic’s PHB is by far the best solution we have seen. We are very confident that we will be able to reduce costs significantly using PHB to manage, interrogate, streamline and audit the whole IP lifecycle for TheraVab,” said TheraVab CEO, Dr. Herbert Chow.

“We have demonstrated PHB can bring about real cost savings and transparency for Live Sciences Companies such as TheraVab. This includes offering solutions of their Clinical Trials, Intellectual Property management, Royalties and Licencing, and Supply Chain management and compliance. What makes our blockchain unique is, it has been purpose built for the healthcare sector. It is based on recognised healthcare standards and provides the efficiencies the healthcare sector is after. It is not a retrofitted financial transactional blockchain”, said dClinic CEO, Dr. Richard Satur.

In the next few months, TheraVab will be exploring project opportunities in the ASEAN region and have engaged Deloitte Southeast Asia as its Financial and Business Advisor. Together with dClinic, TheraVab will also explore manufacturing and clinical trial opportunities in Singapore and Indonesia. Leveraging the PHB, TheraVab will serve as a beacon for other Biotechs wishing to use Blockchain to help bring efficiencies and transparencies into their operations.

For further information about this Life Sciences implementation of dClinic’s PHB, please email

About dClinic

Private Healthcare Blockchain. The World’s first dedicated Healthcare Blockchain company to integrate Healthcare Systems, Clinics and Hospital Assets with a Revolutionary Private Healthcare Blockchain (PHB) for the secure, transparent delivery of Healthcare, Wellness and Vitality Services, promoting Evidence-based Positive Healthcare Outcomes.

Print Friendly, PDF & Email

Become a Fan

Press Contact

Dr. Richard Satur
+61 412 433 167
Contact Us

Image Gallery